PLOZALIZUMAB PLEVISTINAG
UNII P5H59ZL4XA

Substance Identification & Data

This profile provides standardized clinical and technical data for Plozalizumab Plevistinag, uniquely identified by the FDA Unique Ingredient Identifier (UNII) P5H59ZL4XA.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2983832-01-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

P5H59ZL4XA

CAS Registry Number

2983832-01-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PLOZALIZUMAB PLEVISTINAG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C185129

National Cancer Institute reference terminology for clinical and research data.

INN ID

13431

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Plozalizumab Plevistinag

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Plozalizumab Plevistinag. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-447) [VH (Homo sapiens IGHV3-73*01 (86.9%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.10.8] (26-33.51-60.99-106)) (1-117) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 6-G1v3-1 A1.2, A1 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 L1.2>A (235), G1>A (237) (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-219')-disulfide with L-kappa light chain humanized (1'-219') [V-KAPPA (Homo sapiens IGKV2-30*02 (90.0%) -IGKJ5*01 (100%), CDR-IMGT [11.3.9] (27'-37'.55'-57'.94'-102')) (1'-112') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'), V101 (196')) (113'-219')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on average among 220, 226, 229, 219', 220'', 226'', 229'' and 219''' with (3RS)-1-[(28S)-28-{[(2S)-1-{[(2S)-1-{4-[({[(2-{cyclo[(P3'R)-2'-deoxy-2'-fluoro-P-thioadenylyl-(3'→5')-(P2'R)-7-fluoro-7-carba-P-thioinosinylyl-(2'→5')]-N6.1-carbonyl}phenyl)methyl](methyl) carbamoyl}oxy)methyl]anilino}-1-oxopropan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]carbamoyl}-26-oxo-2,5,8,11,14,17,20,23-octaoxa-27-azadotriacontan-32-yl]-2,5-dioxopyrrolidin-3-yl (plevistinag) groups

Immunoglobulin G1, anti-(human CC chemokine receptor CCR2) (human-Mus musculus monoclonal 1D9 γ1-chain), disulfide with human-Mus musculus monoclonal 1D9 κ-chain, dimer, thioether with [P(R)]-2′-deoxy-2′-fluoro-5′-O-[(R)-hydroxymercaptophosphinyl]-N-[2-[[[[[4-[[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-N-(1-oxo-4,7,10,13,16,19,22,25-octaoxahexacos-1-yl)-L-novleucyl-L-valyl-L-alanyl]amino]phenyl]methoxy]carbonyl]methylamino]methyl]benzoyl]-P-thioadenylyl-(3′→5′)-7-fluoro-7-deazainosine cyclic (2′→5′)-nucleotide

Plozalizumab Plevistinag

immunoglobulin G1-kappa, anti-[Homo sapiens CCR2 (chemokine (C-C motif) receptor 2, C-C chemokine receptor 2, CC-CKR-2, CKR-2, monocyte chemoattractant protein 1 receptor, MCP-1-R, CD192)], humanized monoclonal antibody, conjugated, on an average of 3.8-4.4 cysteinyl residues, to dazostinag (a STING agonist) via a cleavable linker

plozalizumab plevistinag [INN]

External Clinical & Regulatory Resources

Previous UNIIP5H4RK2RQ9

Next UNIIP5H9H0GK67